3 Feb 2016
Steve Rees, VP of screening sciences and sample management at AstraZeneca, discusses how combing acoustic liquid handling and mass spectrometry can increase throughput of samples and decrease assay development costs by up to 1000-fold. Find out how AstraZeneca’s partnership with Labcyte will impact metabolomics and drug discovery screening.
AstraZeneca
Steve Rees is Vice-President of Screening Sciences and Sample Management at AstraZeneca with global responsibility for High Throughput Screening and Compound Management. Steve has written more than 60 scientific papers and has spoken at many international symposia including at the Society of Laboratory Automation and Screening (SLAS). He is currently Chair of the SLAS Europe Council .